The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro
Open accessAbstract
Modeling clinically relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI). This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicology. In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and non-parenchymal cells in a defined architecture. Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histologic analysis that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin positive, smooth muscle actin negative quiescent stellates. Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 weeks in culture. To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by standard pre-clinical models, were compared to the structurally related non-toxic drug Levofloxacin. Trovafloxacin induced significant, dose-dependent toxicity at clinically relevant doses (≤ 4uM). Interestingly, Trovafloxacin toxicity was observed without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports. Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compounds with differential profile. Thus, the combination of patient-derived primary cells with bioprinting technology here for the first time demonstrates superior performance in terms of mimicking human drug response in a known target organ at the tissue level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3D bioprinting of tissues and organs
Murphy, S. V., & Atala, A. (2014) · Nature Biotechnology · doi:10.1038/nbt.2958 · Cited by 7,034
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“While human and rodent HSCs maintained in standard monolayer culture on plastic undergo activation to a myofibroblast phenotype with concomitant upregulation of smooth muscle actin (α-SMA), the HSC resident in the interior of the 3D liver tissues express desmin and not α-SMA (Fig 3E and 3F), suggesting that they are c…”
BackgroundThe third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Davis, G. E., & Senger, D. R. (2005) · Circulation Research · doi:10.1161/01.res.0000191547.64391.e3 · Cited by 1,223
Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver
(1980) · Food and Cosmetics Toxicology · doi:10.1016/0015-6264(80)90206-0 · Cited by 691
Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver
Maddrey, W. C. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70192-2 · Cited by 646
Controlling cell interactions by micropatterning in co-cultures: Hepatocytes and 3T3 fibroblasts
Bhatia, S. N., Yarmush, M. L., & Toner, M. (1997) · Journal of Biomedical Materials Research · doi:10.1002/(sici)1097-4636(199702)34:2<189::aid-jbm8>3.0.co;2-m · Cited by 547
In vitro models for liver toxicity testing
Soldatow, V. Y., LeCluyse, E. L., Griffith, L. G., & Rusyn, I. (2013) · Toxicol. Res. · doi:10.1039/c2tx20051a · Cited by 472
Gene Expression Profiles During Hepatic Stellate Cell Activation in Culture and In Vivo
De Minicis, S., Seki, E., Uchinami, H., Kluwe, J., Zhang, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.033 · Cited by 426
Tissue Engineering by Self-Assembly of Cells Printed into Topologically Defined Structures
Jakab, K., Norotte, C., Damon, B., Marga, F., Neagu, A., Besch-Williford, C. L., Kachurin, A., Church, K. H., Park, H., Mironov, V., et al. (2008) · Tissue Engineering Part A · doi:10.1089/tea.2007.0173 · Cited by 378
Hepatic stellate cells require a stiff environment for myofibroblastic differentiation
Olsen, A. L., Bloomer, S. A., Chan, E. P., Gaça, M. D. A., Georges, P. C., Sackey, B., Uemura, M., Janmey, P. A., & Wells, R. G. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00412.2010 · Cited by 355
Multi-cell type human liver microtissues for hepatotoxicity testing
Messner, S., Agarkova, I., Moritz, W., & Kelm, J. M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0968-2 · Cited by 319
Uetrecht, J. P. (1999) · Chemical Research in Toxicology · doi:10.1021/tx980249i · Cited by 304
Tissue Engineering by Self-Assembly of Cells Printed into Topologically Defined Structures
Jakab, K., Norotte, C., Damon, B., Marga, F., Neagu, A., Besch-Williford, C. L., Kachurin, A., Church, K. H., Park, H., Mironov, V., et al. (2007) · Tissue Engineering · doi:10.1089/ten.2007.0173 · Cited by 273
Kostadinova, R., Boess, F., Applegate, D., Suter, L., Weiser, T., Singer, T., Naughton, B., & Roth, A. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.01.012 · Cited by 262
Self-citationHuman liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing
Tostões, R. M., Leite, S. B., Serra, M., Jensen, J., Björquist, P., Carrondo, M. J. T., Brito, C., & Alves, P. M. (2012) · Hepatology · doi:10.1002/hep.24760 · Cited by 246
KAPLOWITZ, N., AW, T. Y., SIMON, F. R., & STOLZ, A. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-6-826 · Cited by 240
Mitochondrial abnormalities—A link to idiosyncratic drug hepatotoxicity?
Boelsterli, U. A., & Lim, P. L. K. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.013 · Cited by 232
Idiosyncratic Liver Injury: Challenges and Approaches
Watkins, P. B. (2005) · Toxicologic Pathology · doi:10.1080/01926230590888306 · Cited by 166
Shaw, P. J., Hopfensperger, M. J., Ganey, P. E., & Roth, R. A. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm218 · Cited by 159
Naisbitt, D. J., Gordon, S. F., Pirmohamed, M., & Park, B. (2000) · Drug Safety · doi:10.2165/00002018-200023060-00002 · Cited by 146
Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J., & Owen, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-13 · Cited by 138
Review article: diagnosis and treatment of non‐alcoholic fatty liver disease
OH, M. K., Winn, J., & Poordad, F. F. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03752.x · Cited by 137
Inflammation and Drug Idiosyncrasy—Is There a Connection?
Roth, R. A., Luyendyk, J. P., Maddox, J. F., & Ganey, P. E. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041624 · Cited by 137
Waring, J. F., Liguori, M. J., Luyendyk, J. P., Maddox, J. F., Ganey, P. E., Stachlewitz, R. F., North, C. M., Blomme, E. A. G., & Roth, R. A. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.096347 · Cited by 127
Layered Patterning of Hepatocytes in Co-Culture Systems using Microfabricated Stencils
Cho, C. H., Park, J., Tilles, A. W., Francois Berthiaume, B., Toner, M., & Yarmush, M. L. (2010) · BioTechniques · doi:10.2144/000113317 · Cited by 126
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions
Uetrecht, J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02816-2 · Cited by 125
Shaw, P. J., Ganey, P. E., & Roth, R. A. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq168 · Cited by 123
Idiosyncratic toxicity: the role of toxicophores and bioactivation
Williams, D. P., & Park, B. K. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02888-5 · Cited by 111
Otu, H. H., Naxerova, K., Ho, K. J., Can, H., Nesbitt, N. T., Libermann, T. A., & Karp, S. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608441200 · Cited by 90
Kegel, V., Pfeiffer, E., Burkhardt, B., Liu, J. L., Zeilinger, K., Nussler, A. K., Seehofer, D., & Damm, G. (2015) · Mediators of Inflammation · doi:10.1155/2015/640631 · Cited by 50
CASE REPORT: Trovafloxacin Hepatotoxicity
Lazarczyk, D. A., Goldstein, N. S., & Gordon, S. C. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1010741510046 · Cited by 47
Insight into hepatotoxicity: The troglitazone experience†
Watkins, P. B. (2005) · Hepatology · doi:10.1002/hep.20598 · Cited by 45
Mello, W. C. D. (2018) · CRC Press eBooks · doi:10.1201/9781351070461 · Cited by 23
Are We Closer to Finding Biomarkers for Identifying Acute Drug-Induced Liver Injury?
Antoine, D. J., Lewis, P. J. S., Goldring, C. E., & Park, B. K. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.42 · Cited by 19
Antimicrobial‐Associated Acute Hepatitis
Nicholson, S., Webb, C. D., & Moellering, R. C. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.9.794.34066 · Cited by 18
American Society for Cell Biology
(1960) · Nature · doi:10.1038/187649g0 · Cited by 7
Research works printed but not linked: 1
- DG Nguyen, 2016, Engineered Renal Tissues, Arrays Thereof, and Methods of Making the Same, United States of America Patent Office
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Printability and shape fidelity of bioinks in 3D bioprinting
Schwab, A., Levato, R., D’Este, M., Piluso, S., Eglin, D., & Malda, J. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00084 · Cited by 1,359
Advances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Biofabrication: A Guide to Technology and Terminology
Moroni, L., Boland, T., Burdick, J. A., De Maria, C., Derby, B., Forgacs, G., Groll, J., Li, Q., Malda, J., Mironov, V. A., et al. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.10.015 · Cited by 636
3D bioprinting of tissues and organs for regenerative medicine
Vijayavenkataraman, S., Yan, W.-C., Lu, W. F., Wang, C.-H., & Fuh, J. Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.004 · Cited by 630
Metadata
- Authors
- Nguyen, D. G., Funk, J., Robbins, J. B., Crogan-Grundy, C., Presnell, S. C., Singer, T., & Roth, A. B.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-07-07
- Volume
- 11
- Issue
- 7
- Pages
- e0158674
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2462042948
- Cited by
- 379
- References
- 39
- FWCI
- 49.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.